Trials / Completed
CompletedNCT02659384
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in advanced recurrent platinum-resistant ovarian cancer patients in order to select the optimal treatments for further development in Phase III.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | |
| DRUG | atezolizumab | |
| DRUG | acetylsalicylic acid | |
| DRUG | placebo |
Timeline
- Start date
- 2016-12-23
- Primary completion
- 2021-06-01
- Completion
- 2022-03-01
- First posted
- 2016-01-20
- Last updated
- 2023-03-14
Locations
12 sites across 5 countries: France, Netherlands, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02659384. Inclusion in this directory is not an endorsement.